Hemab Therapeutics Holdings Executive Compensation
Hemab Therapeutics Holdings, Inc. has appointed Keli Walbert to its Board of Directors and Audit Committee, effective September 24, 2026. Ms. Walbert will receive an annual cash retainer of $40,000 for board service plus $10,000 for committee service, along with an initial grant of options to purchase 36,000 shares of common stock vesting over three years. This appointment fills a Class I director seat with a term expiring at the 2027 annual meeting.
- Counterparty
- Keli Walbert